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Abstract: Quercetin (Q), a flavonoid found in berries and 
onions, can reduce blood pressure in hypertensive animals and 
inhibit signal transduction pathways in vitro that regulate 
cardiac hypertrophy. We hypothesized that quercetin could 
prevent cardiovascular complications in rats with abdominal 
aortic constriction (AAC). Rats consumed standard or Q- 
supplemented chow (1.5 g Q/kg chow) for 7 days before A A C  or 
sham surgery (SHAM , n = 15; A A C , n = 15; SHAM Q , n = 15; 
A A CQ , n = 14). Fourteen days after surgery, plasma and liver 
Q concentrations were elevated (P < 0.05) and hepatic lipid 
oxidation was reduced (P  < 0.05) in Q-treated versus untreated 
rats. Carotid arterial blood pressure and cardiac hypertrophy 
were attenuated (P < 0.05), and cardiac protein kinase C  p il 
translocation was normalized (P  < 0.05) in A A C Q  versus A A C . 
Expression of cardiac p-myosin heavy-chain m RNA  was also 
reduced in A A C Q  versus A A C  (P < 0.05). However, extra­
cellular regulated kinase 1/2 phosphorylation was similar in 
A A C  versus A A CQ . The level of aortic endothelial dysfunction 
(wire myography) was also similar between A A C  and A A C Q , in 
spite of reduced aortic thickening in A ACQ . Importantly, Q- 
treated rats did not show any deleterious changes in myocardial 
function (echocardiography). Our data supports an antihyper­
tensive and antihypertrophic effect of Q in vivo in the absence of 
changes concerning vascular and myocardial function.
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^ ''a rd ia c  hypertrophy has been associated with an 
increased risk of developing heart failure or death.1 
As such, there is interest in preventing and treating risk 
factors such as hypertension and myocardial infarction 
that contribute to the development of cardiac hypertro­
phy. Chronic high blood pressure increases the afterload 
experienced by the heart, which in turn increases wall 
stress and stimulates development of cardiac hypertro­
phy. The antioxidant quercetin (Q), a flavonoid found in 
onions, apples, red wine, and berries, may be an effective 
agent to reduce blood pressure and prevent cardiac 
hypertrophy. Spontaneously hypertensive rats with estab­
lished high blood pressure that are treated daily with oral 
Q experience a drop in blood pressure, reduced cardiac 
hypertrophy, and improved vascular function." Other 
studies using mice and guinea pigs with surgically induced 
pressure overload (aortic constriction) have reported that 
prior treatment with various antioxidants can actually 
prevent cardiac hypertrophy.3’4 Taken together, these 
studies suggest that antioxidants such as Q may be 
efficacious in preventing/treating hypertension and cardi­
ac hypertrophy in at least 2 unique models of cardiovas­
cular disease, systemic hypertension and aortic 
constriction. Interestingly, epidemiological studies have 
also reported that Q intake is inversely related to ischemic 
heart disease and a number of other chronic diseases such 
as lung cancer, type 2 diabetes mellitus, and asthma.5’6 
Cardiac hypertrophy stimulated by an increase in 
blood pressure and wall stress is thought to be regulated 
by a number of signal transduction pathways including 
protein kinase C (PKC), extracellular regulated kinase 1/2 
(ERKI/2), and Akt. Neurohormonal factors such as 
angiotensin II (a product of the rennin-angiotensin 
system), endothelin-I, and phenylephrine are activators 
of PKC, which can in turn activate ERKI/2 during 
conditions of pathological hypertrophy.8 11 The role of 
Akt in cardiac hypertrophy is more complex because of 
the contrasting effects of its upstream activator, phos- 
phoinositol 3 kinase (PI3K). Activation of Akt by the 
PI3Ka isoform is involved in physiological hypertrophy, 
whereas PI3Ky-mediated Akt activation can be a 
regulator of pathological cardiac hypertrophy.7’12 14
The aim of the present study was to evaluate the 
mechanisms by which dietary Q could attenuate cardiac 
hypertrophy in the setting of a fixed aortic constriction.
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We hypothesized that blood pressure and cardiac 
hypertrophy would be attenuated in rats that consume a 
Q-supplemented diet before a pressure overload challenge 
consisting of 14 days of abdominal aortic constriction 
(AAC). In addition, we hypothesized that signaling 
pathways regulating cardiac hypertrophy (eg, PKC, 
Akt, ERK1/2) would be less activated in Q-treated 
animals. To determine whether any reduction in cardiac 
hypertrophy and signal transduction activation was 
associated with a general reduction in oxidative stress, 
indices of hepatic lipid and protein oxidation were 
quantified. Finally, myocardial and vascular function 
were measured to assess the effect of Q consumption on 
structure and function of the heart and selected vessels.
MATERIALS AND METHODS 
Animals and Diets
All protocols were approved by the University of 
Utah Institutional Animal Care and Use Committee. 
Adult, male Sprague-Dawley rats (250 g) were selected 
randomly and given free access to standard chow (AIN 
93M, Research Diets, New Brunswick, NJ) or chow 
supplemented with Q aglycone (Q; AIN 93M + 1.5 g Q/kg 
chow; Sigma, St Louis, MO) for 7 days. This dose was 
chosen based on a previous study wherein cardiac 
hypertrophy was attenuated in pressure overloaded mice 
receiving 120 mg/kg Q intraperitoneally (IP).15 Dietary 
administration was chosen to establish clinical relevance 
to human dietary habits. The estimated Q intake of rats 
fed diets with 1.5 g Q/kg chow was 130 mg/kg.16 This 
estimate is based on an average consumption of 10 g 
chow/100 g body weight for a rat.16 A recent study 
examining humans given a supplement of Q aglycone, the 
isoform used in the present study, reported the half-life of 
circulating metabolites to be 15 to 18 h.17 In addition, the 
level of Q used in these studies (0.15% diet by weight) is 
«  10 times lower than the levels at which the first signs of1 Snephrotoxicity are observed in the male rat. On day 8, 
suprarenal AAC using a hemoclip with an internal 
diameter of 0.63 mm or a sham operation (SHAM) was 
performed. Rats continued their respective diets for 14 
more days, including the day of surgery. This duration of 
AAC produces 20% to 35% increases in heart weight: - 
body weight.19 Data were compared among SHAM 
(n = 15), AAC (n = 15), SHAMQ (n = 15), and AACQ 
(n = 14) rats.
Myocardial Function
Cardiac function was determined in a subset of 
animals 12 to 13 days after surgery using echocardio­
graphy, as we have described.20 Briefly, rats were 
anesthetized with ketamine (50-75 mg/kg, IP) and xyla- 
zine (10-15 mg/kg, IP) and 2D-guided M-mode images of 
the left ventricle were obtained using a General Electric 
Vivid 5 echocardiographic machine equipped with a 10- 
MHz transducer. Digital images were analyzed offline by 
a blinded observer.
Arterial Blood Pressure and Tissue Sampling
Fifteen days postsurgery, all rats were anesthetized 
using isoflurane (3%-5%) and fluid-filled catheters were 
inserted into the carotid and caudal arteries.21 After 
animals regained consciousness and recovered for 60 min, 
arterial blood pressures and heart rate were measured 
over «  20 cardiac cycles (Biopac Systems, Santa Barbara, 
CA). Next, an arterial blood sample was taken for Q 
analysis. Finally, rats were anesthetized deeply using 5% 
isoflurane, the chest opened, and heart, sections of liver, 
segments of thoracic aorta, and mesenteric arteries were 
removed. The heart was placed immediately in iced 
physiological saline solution, trimmed of adherent tissue, 
and weighed. The apical portion of the left ventricle (LV) 
was excised and used to analyze signaling proteins. 
Coronary arteries were dissected from the remaining 
portion of the LV and used to determine reactivity. 
Sections of liver were excised and prepared for quantifi­
cation of quercetin, thiobarbituric acid reactive sub­
stances, and protein carbonyls. Segments of thoracic 
aorta were used to determine function and medial 




Cardiac lysates containing cytosolic and membrane 
proteins were prepared from the LV previously frozen at 
— 80°C, as previously detailed.22 All extraction proce­
dures were performed at 4°C. Protein concentration was 
determined using a Bio-Rad Protein assay (Bio-Rad, 
Hercules, CA) with bovine serum albumin as a standard.
ERK1/2, Akt, Serine Phosphorylated PKC Substrates
All homogenization procedures were performed at 
4°C. The LV was homogenized with a tissuemizer in 1 mL 
of ice-cold R1PA buffer (50mmol/L Tris-HCl, pH 7.4, 
150mmol/L NaCl, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 1 mmol/L sodium orthovanadate, 1 mmol/ 
L NaF, and 10 nL/mL Sigma protease inhibitor cocktail 
[Sigma, St Louis, MO]). After homogenization, the 
samples were sonicated twice on ice and centrifuged at 
ll,000g for 10min at 4°C. Supernatants were recovered 
and stored at — 80°C for subsequent immunoblotting. 
Protein concentration was determined using a Bio-Rad 
Protein assay with bovine serum albumin as a standard.
Western Blotting Analysis
Electrophoresis and transfer of proteins to poly- 
vinylidene difluoride membranes were done as previously 
described.22 Primary antibody directed against PKCa, pi, 
PII, e, and 8 (Santa Cruz Biotechnology, Santa Cruz, CA) 
were incubated overnight at 4°C in a 1:1000 dilution. 
Antibodies directed against total and phospho ERK1/2, 
Akt, and serine phosphorylated PKC substrates (Cell 
Signal Technology, Beverly, MA) were incubated at a 
1:1000 dilution for 48 h at 4°C in 5% bovine serum 
albumin (phosphospecific antibodies) or 5% nonfat milk 
(nonphosphospecific antibodies) in Tris buffer with
5 3 2 C 2006 Lippincott Williams & Wilkins
/ Cardiovasc Pharmacol™ • Volume 47, Number 4, April 2006 Quercetin and Pressure Overload Hypertrophy
0.05% Tween-20. Secondary antibody conjugated to 
horseradish peroxidase (goat anti-rabbit, Cell Signal 
Technology) was incubated for lh  at 1:10,000 dilution, 
a-tubulin band density (Santa Cruz Biotechnology), 
previously shown to be unchanged in compensated 
cardiac hypertrophy,23 was used as a loading control. 
Signals were visualized by enhanced chemiluminescence 
(Cell Signal Technology). Relative band density of 
immunoblots on film was measured with a scanner using 
NIH 1.63 image software (National Institutes of Health, 
Rockville, MD).
RNA Isolation and Real-Time Polymerase Chain 
Reaction
Total RNA was isolated from left ventricle using 
TRIZOL reagent (Invitrogen) according to the manufac­
turer’s instructions. Reverse transcription was carried out 
with SuperScript II Reverse Transcriptase (Invitrogen) 
and random primers following the manufacturer’s in­
structions. Forward and reverse primers used for ampli­
fication of fully processed cardiac (3-myosin heavy chain 
(P-MHC) were based on those previously reported24 
[reverse primer (3-MHC5869R (5'-CTCCAGGTCT- 
CAGGGCTTCAC-3'), forward primer (3-MHC5579F 
(5'-GACAGGAAGAACCTACT GCG-3')]. Glyceralde- 
hyde-3-phosphate dehydrogenase (GAPDH) was used 
as a control. GAPDH primers sequences were (Genbank 
accession no. NM 017008) forward (5'-GCCATCAAC- 
G ACCCCTT CAT - 3') and reverse (5'-CCGCCTGCT- 
TCACCACCTTC-3'). All real-time polymerase chain 
reaction experiments were done in triplicate using 2ng 
of RNA and run for 25 to 26 cycles. Polymerase chain 
reaction products were resolved on 2% agarose gels with 
ethidium bromide and quantitated by densitometry using 
NIH Image vl.64 software.
Vascular Reactivity
Thoracic aortae (proximal to the site of aortic 
constriction and thus exposed to pressure overload), 
coronary arteries, and mesenteric arteries (distal to the 
aortic constriction and thus not exposed to pressure 
overload) were mounted on wire-type myographs25 and 
warmed to 37°C for 30 min at zero tension. At 30 min, 
coronary (10 mg) and mesenteric (50 mg) arterial tension 
was increased manually. Next, a series of internal 
circumference-active tension curves were constructed to 
determine the vessel diameter that evoked the greatest 
tension development (Lmax) to lOOmmol/'L potassium 
chloride (KC1). Lmax tension did not differ among groups 
and was 492 ± 48 and 803 ± 56 mg for coronary and 
mesenteric arteries, respectively. Tension on the aortas 
was increased manually over 60 min to «  2 g and did not 
differ among groups (1979 ± 14mg). The vessel bathing 
medium was exchanged at «  15 min intervals throughout 
the experiment with physiological saline solution (pH 
7.35-7.45). Vasorelaxation responses to acetylcholine 
(ACh, 10^8-10^4mmol/'L) and sodium nitroprusside 
(SNP, 10^9-10^4mmol/'L), and vasocontraction pro­
duced by iy°-monomethyl-L-arginine (l-NMMA,
10 3mmol/'L), were assessed on vessels precontracted 
with norepinephrine (NE, 10^7mmol/'L; aorta, mesen­
tery)26 or endothelin-1 (ET-1; « 3 x  10^8mmol/L, cor­
onary). Vasocontractile responses to KC1 (10-100 mmol/' 
L; all vessels) and NE (10^8-10^4mmol/'L; aorta and 
mesentery only) also were assessed. Protocols were 
separated by 45 to 60 min. For all vessels studied: 
vasorelaxation is expressed as percent relaxation from 
precontraction tension; and vasocontraction is presented 
as milligrams of developed tension (NE, KC1, ET-1) or as 
percent increase from precontraction tension (l-NMMA). 
We have used these procedures previously.27, 8
Plasma and Tissue Q Analyses
Samples were analyzed for free Q, conjugated Q, 
and 3-O-methyl Q (a metabolite). Approximately 30 mg 
of tissue was placed in a 12- x 75-mm glass test tube along 
with 200 mL KH2P 04 (pH 4.5) and glass beads. Samples 
were homogenized by inserting a 10- x 75-mm tube into 
the 12- x 75-mm tube, then rinsing the outside of the 10- 
x 75-mm tube with an additional 200 mL KH2P04 (pH 
4.5). The homogenate was then incubated with 20 mL of 
(3-glucuronidase at 40°C for 2h. Samples were acidified 
with 40 mL of dilute phosphoric acid (1:10) to inhibit 
protein binding and gently mixed with 2mL of hexane/' 
acetic acid (1:1). Samples were cooled at — 60°C for 
10 min and the solvent decanted from the frozen aqueous 
layer into clean 12- x 75-mm tubes. The extraction 
process was repeated with 2-mL hexane/'acetic acid (1:1) 
and the organic phases combined. The solvent was then 
dried under N2 at 40°C, and the residue reconstituted in 
100-mL mobile phase for HPLC analysis.
Estimates of Liver Oxidant Load
Lipid oxidation was determined by fluorescence 
detection of malondialdehyde equivalents (nmol/'mg 
protein) as previously described.2; Protein oxidation 
was estimated by quantifying protein carbonyls (nmol/ 
mg protein) via spectrophotometric quantification of the 
dinitrophenylhydrazine adduct.29 For all assays, protein 
concentrations were determined using bovine serum 
albumin as the standard.30
Vascular Morphology
Thoracic aortas were fixed in formalin (24 h) and 
embedded in paraffin before three 4-nmol/'L cross­
sections were mounted on slides and stained with 
hematoxylin and eosin. Images were taken with a 
microscope (Nikon E6000) equipped with a digital 
camera (Q imaging, Micro Publisher 5.0 RTV) using 
2 x objective. Final focus (microscope objective and 
digital camera optical zoom) used for capturing digital 
images was 4 x. Software was calibrated using a micro­
meter photographed at the same focus and zoom so that 
pixels were expressed as microns. Tunica media thickness 
was measured from calibrated digital photographs using 
NIH Image 1.32 software.28
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Statistical Analyses
A two-way analysis of variance was used to detect 
differences among groups using SPSS vlO (SPSS, 
Chicago, IL). When a significant P value was obtained 
(P < 0.05), post hoc procedures were performed using 
least-squares difference analyses to identify individual 




Body weight (g) was not different among SHAM 
(335 ± 7), AAC (321 ± 6), SHAMQ (342 ± 10), and 
AAC-Q (342 ± 7) animals. Plasma (jig/mL) and liver 
(ng/mg protein) concentrations of Q isoforms (free Q, 
conjugated Q, free 3-O-methyl Q, conjugated 3-O-methyl 
Q) were similar in Q-fed groups and undetectable in 
control-fed groups (Table 1).
Cardiac Hypertrophy, Arterial Pressure, and 
Aortic Medial Thickening
AAC evoked greater heart: body weight compared 
to SHAM animals. This hypertrophic response was 
attenuated in AACQ rats (Fig. 1A). Q treatment had no 
effect on cardiac size in SHAMQ animals (Fig. 1A). Lung 
and liver weights were similar among groups, verifying 
the absence of pulmonary and hepatic congestion. AAC 
increased the carotid arterial systolic, diastolic, and mean 
blood pressures (Fig. IB) and elevated the carotid-caudal 
arterial blood pressure gradient relative to SHAM and 
SHAMQ. Carotid systolic pressure was attenuated in 
AACQ versus AAC, but carotid diastolic and mean 
arterial pressures were normal compared to SHAM and 
SHAMQ (Fig. IB). The carotid-caudal gradient was also 
lower in the AACQ versus AAC animals (Fig. 1C). 
Systolic, diastolic, and mean caudal pressures (ie, distal to 
the aortic constriction) were not different among groups 
(data not shown). Medial thickness of aortas was greater 
in AAC compared with all other groups, including AACQ 
(Fig. ID). Finally, there was a strong correlation 
(r = 0.804, r2 = 0.647, P < 0.001) between mean arterial 
blood pressure and cardiac hypertrophy as determined by 
heart weight: body weight, which emphasized the central 
role of blood pressure in determining cardiac mass in 
these animals (Fig. IF). |I-MIIC mRNA expression
TABLE 1. Concentrations of Quercetin (Q) Isoforms in Livers 
(ng/mg protein) and Plasma (ng/mL) of Rats Fed Q- 
Supplemented Diets
SHAMQ (n = 5) AACQ (n = 5)
Liver Q 0.09 ±  0.03 0.12 ±  0.04
Liver conjugated Q 0.17 ±  0.04 0.19 ±  0.03
Liver 3 -0-m ethv l Q 0.19 ±  0.07 0.14 ±  0.05
Liver conjugated 3-0-m ethy l Q 1.05 ±  0.10 1.30 ±  0.10
Plasm a Q* 3.26 ±  0.05 3.96 ±  0.40
* All isoforms of Q combined.
normalized to GAPDH expression (determined by 
quantitative densitometry) was increased in left ventricles 
of AAC versus AACQ, SHAM, and SHAMQ (Fig. 1G). 
These data indicate that Q treatment prevented the 
increase in cardiac |l-Ml IC expression typically observed 
in AAC.
Myocardial Function
Heart rate (bpm) was similar among SHAM 
(389 ± 10), AAC (390 ± 10), SHAMQ (392 ± 10), and 
AACQ (413 ± 10) rats. Echocardiographic estimates of 
LV mass indicated that AAC-evoked increases in LV 
mass (g; 1.55 ± 0.19) were abolished in AACQ 
(1.19 ±0.07) animals (Fig. IE). SHAM (1.08 ± 0.08) 
and SHAMQ (1.17 ± 0.10) had similar LV mass. There 
were no differences in cardiac output, ejection fraction, 
and fractional shortening among groups, indicating that 
cardiac function was normal in both AAC and AACQ 
compared with sham groups.
Vascular Reactivity
Vessel characteristics are shown in Table 2. ACh- 
evoked vasorelaxation was less in thoracic aortas from 
AAC versus SHAM animals regardless of Q treatment 
(Fig. 2A), whereas responses from the coronary and 
mesenteric arteries were similar among groups (Fig. 2B, 
C). For all vessel types (aorta, coronary, mesentery), 
SNP-evoked dose-response curves (10_9-10_4mmol/L) 
were not different among the 4 groups, demonstrating 
that a functional smooth muscle layer existed (Table 3). 
Precontraction tension between the ACh and SNP dose- 
response curves was similar for all groups and all vessel 
types. Basal nitric oxide synthase activity, estimated as 
tension development in response to l -N M M A . was 
similar among groups for all vessel types (Table 3). 
Likewise, receptor-mediated (ie, NE 10_ t-10_4mmol/L, 
aorta and mesentery) and nonreceptor mediated (KCl, 
10-100 mmol/L, all vessels) contractile responses were not 
different among groups (Table 3).
Signaling Proteins
PKCpiI translocation was greatest in LV tissue 
from AAC versus AACQ, SHAM, SHAMQ rats, whereas 
PKCoc, PKCpi, PKC8, or PKCs were similar among all 
groups (Fig. 3A, B). Increased membrane levels of 
PKCpiI in AAC rats coupled with no change in cytosolic 
levels suggested increased PKCpiI protein expression, 
which was verified by greater protein levels of PKCpiI 
from whole heart homogenates in AAC versus all other 
groups (Fig. 3C). Although serine phosphorylation of 
endogenous PKC substrates normalized to oc-tubulin 
levels was greater in AAC, AACQ versus SHAM, 
SHAMQ (Fig. 3D), no differences existed between AAC 
and AACQ rats. None of the measured PKC isoforms 
were altered in SHAMQ rats (Fig. 3A, B). In contrast, 
both AAC and AACQ rats had increased ERKI/2 
activation (p-ERK: total ERK) compared to SHAM 
and SHAMQ (Fig. 4). Activation of Akt (p-Akt: total 
Akt) was similar among groups (data not shown).
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FIGURE 1. A, AACQ rats have less cardiac 
hypertrophy than AAC. *P<0.05 versus 
SHAM, SHAMQ, AACQ **P<0.05 versus 
SHAM, SHAMQ, AAC. B, AACQ rats have 
lower systolic carotid pressure and normal 
diastolic and mean arterial pressure com­
pared to AAC rats. *P<0.05 versus SHAM, 
SHAMQ AACQ **P<0.05 versus SHAM, 
SHAMQ AAC. C, The pressure gradient 
across the site of aortic constriction is lower 
in AACQ rats versus AAC. *P<0.05 versus 
SHAM, SHAMQ, AACQ **P<0.05 versus 
SHAM, SHAMQ AAC. D, Aortic hypertro­
phy is prevented in AACQ animals as 
determined by medial thickness (|am; 
n = 5/group, 3-5 sections/animal). Magnifi­
cation level used for analysis was 4 x . 
*P<0.05 versus SHAM, SHAMQ, AACQ. E, 
M-mode images demonstrate that AAC rats 
had greater wall thickening than AACQ 
(n = 5/group). F, Regression analysis of 
heart:body weight versus carotid arterial 
pressure. A strong correlation exists be­
tween blood pressure and cardiac hyper­
trophy. G, p-MHC mRNA expression 
normalized to GAPDH mRNA is increased 
60% in AAC versus SHAM, but normalized 
in AACQ. *P<0.05 versus SHAM, SHAMQ, 
and AACQ. Results are average of 3 
independent trials. SHAM, sham operated 
and fed control chow; SHAMQ sham 
operated and fed Q-enriched chow; AAC, 
abdominal aortic constriction and fed con­
trol chow; AACQ abdominal aortic constric­
tion and fed Q-enriched chow.
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Estimates of Oxidant Load
Th iobarb itu rie  acid reactive substances (nmol 
malondialdchydc/'mg protein) were lower in liver 
from S H A M Q  and A A C Q  rats compared to S H A M  
and A A C  animals (F ig . 5). There was a trend toward  
lower (P  =  0.058) liver protein carbonyls (nmol/'mg 
protein) in Q-treated versus untreated rats (S H A M Q
1.42 ± 0 .1 1 : A A C Q  1.34 ± 0.13: S H A M  1.62 ± 0.18: 
A A C  1.70 ± 0.10).
DISCUSSION
The m ajor finding o f this study was that A A C  rats 
consum ing the flavonoid Q  had less card iac hypertrophy  
compared with untreated A A C  rats. The most like ly
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TABLE 2. Vessel Characteristics
SH A M AAC SH A M Q  A A C Q
A o rta  
Baseline 
in ternal 
diam eter, jim 
In ternal 
diam eter a t 2g  
tension, jim 
Vessel length, jim 
M esentery
Baseline in ternal 
diam eter, jim 
In ternal diam eter 
a t Lmax?
Vessel length, jim 
C oronary
Baseline in ternal 
diam eter, jim 
In ternal diam eter 
a t 2g  tension, jim 
Vessel length, jim
1686 ±  46 1680 ±  32 1629 ±  41 1658 ±  29
2694 ±  35 2780 ±  28 2774 ±  35 2767 ±  37
3314 ± 7 0  
188 ±  13 
463 ±  10 
3859 ±  134 
125 ±  8 
347 ±  16 
1223 ±  47
3443 db 48 
186 ±  22 
455 ±  19 
4216 db 150 
126 ±  3 
376 db 18 
1300 db 35
3348 db 61 
175 db 11 
485 db 26 
4094 db 122 
122 db 1  
381 db 20 
1339 db 43
3346 db 66 
195 db 9  
445 db 26 
4148 db 224 
128 db 8 
389 db 16 
1293 db 39
mechanism for this effect is a decreased arterial blood 
pressure and a secondary reduction in the activation of 
hypertrophic signaling pathways in the heart. These data 
support our original hypothesis and agree with previous 
studies that oral administration of Q attenuates blood 
pressure in spontaneously hypertensive rats2 and rats with 
hypertension evoked by chronic nitric oxide synthase 
inhibition.31 Furthermore, the structural and hemody­
namic benefits we observed in AACQ animals were not 
accompanied by deleterious changes to myocardial or 
vascular function. Our results contribute importantly to a 
growing body of literature concerning the potential for 
polyphenolic compounds to reduce indices of cardiovas­
cular risk.32-36
Originally we hypothesized that reduced cardiac 
hypertrophy in AACQ would be accompanied by reduced 
activation of PKC and/or ERK1/2. Although this 
hypothesis was supported by the observation that Q 
consumption normalized PKCpiI translocation in 
AACQ, cardiac ERK1/2 activation persisted in these 
animals. The cause for this finding is unclear, but it may 
be related to the mild degree of hypertension that was 
present in AACQ rats compared with the severe 
hypertension experienced by AAC animals. However, 
despite normal translocation levels of PKC isoforms in 
AACQ hearts, levels of serine phosphorylated PKC 
substrates increased similarly between AAC and AACQ 
hearts. Although the cause of this cannot be defined 
precisely, PKC isoforms not examined in the present 
study may have remained activated in AACQ and 
contributed to serine phosphorylation.
Previous studies have reported that antihypertensive 
drugs can reduce cardiac hypertrophy in pressure-over­
loaded rats;37,38 however, little is known about the effect 
on cardiac PKC activation following blood pressure 
reduction. Fedorova et al reported that hypertensive Dahl 
salt-sensitive rats treated with cicletanine (antihyperten­
sive) had reduced blood pressure, cardiac PKCpiI
FIGURE 2. (A) ACh-evoked vasorelaxation in aortas; (B) 
mesenteric arteries; and (C) coronary arteries. SHAM, sham 
operated and fed control chow; SHAMQ, sham operated and 
fed Q-enriched chow; AAC, abdominal aortic constriction 
and fed control chow; AACQ, abdominal aortic constriction 
and fed Q-enriched chow. Data are mean + SE. *P<0.05 versus 
SHAM, SHAM Q.
translocation, and cardiac hypertrophy.39 The authors of 
that study suggested that because cicletanine is also a 
PKC inhibitor in vitro, cardiac PKCpiI inhibition may 
have occurred at least in part because of the direct effects 
of cicletanine on PKC itself. Along these lines, previous 
investigations have also reported that Q can also inhibit 
PKC in vitro via competitive inhibition when adenosine 
triphosphate (ATP) and Q concentrations are similar.40
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TABLE 3. Vessel Reactivity Data
SH A M AAC S H A M Q A A C Q
A o rta
M axim al % relaxation , 1CTJ m m ol/L  SN P 88 ± 4 92 ± 6 85 ±  4 85 ±  5
% tension developm ent, 10 m m ol/L  l-N M M A 19 ±  2 15 ±  2 19 ±  2 20 ±  2
m g tension  developm ent, 10 4 m m ol/L  N E 2336 ±  38 1767 ±  183* 2197 ±  154 1706 ±  114*
m g tension  developm ent, 100 m m ol/L  K C l 1937 ±  69 1804 ±  128 1846 ±  67 1912 ±  70
M esentery
M axim al % relaxation , 10 m m ol/L  SN P 96 ± 4 92 ± 6 106 ±  4 94 ±  4
% tension developm ent, 10 m m ol/L  l-N M M A 8 ±  3 15 ±  2 19 ±  2 20 ±  2
m g tension  developm ent, 10 4 m m ol/L  N E 1962 ±  165 1920 ±  65 2032 ±  132 1992 ±  100
m g tension  developm ent, 100 m m ol/L  K C l 957 ±  32 841 ±  43 907 ±  62 875 ±  149
C oronary
M axim al % relaxation , 10 m m ol/L  SN P 96 ± 4 92 ± 6 106 ±  4 94 ±  4
% tension developm ent, 1 0 M  l-N M M A 19 ±  2 15 ±  2 19 ±  2 20 ± 2
m g tension  developm ent, 100 m m ol/L  K C l 476 ±  28 498 ±  88 534 ±  120 585 ±  143
Responses in aorlas and mesentery lo SNP and l-NMMA were performed on vessels precontracted with NE. Responses 
were performed on vessels precontracted with endolhelin-1. KCl, potassium chloride.
in coronary arteries lo SNP and l-NMMA
*P < 0.05 vs respective control group.
However, we do not believe our findings observed in vivo 
can be attributed to a direct effect of Q on PKCpiI. In 
this regard, ATP concentrations are «  5 nmol/g wet heart 
weight in the rat,41 whereas plasma and liver Q 
concentrations in our animals were much lower (Table 
1). Because of the competitive relationship between ATP 
and Q and the differences in their respective concentra­
tions, it is unlikely that Q directly inhibited PKCpiI in 
AACQ rats. Furthermore, given the mechanism of Q 
inhibition of PKC, only the catalytic activity of PKC 
would be affected, not the translocation of the enzyme as 
measured in our study.
The reduction of myocardial PKCpiI translocation 
we observed in AACQ versus AAC rats is likely 
secondary to the blood pressure-lowering effects of Q 
(ie, the stimulus to activate hypertrophic signaling kinases 
was reduced). At least 1 other study provides evidence to 
support this statement. When chronically hypoxic rats 
with pulmonary hypertension were treated with nifedi­
pine, right ventricular hypertrophy was lower and PKC 
expression normalized.42 Further evidence supporting our 
contention that lower blood pressure was responsible for 
reduced cardiac hypertrophy is provided by the strong 
correlation between blood pressure and cardiac mass 
(r = 0.804, P<  0.001). Although previous investigations 
report that antihypertensive drugs reduce cardiac hyper­
trophy in pressure-overloaded rats,37’38 our study is the 
first to show that the polyphenolic compound Q reduces 
arterial pressure, cardiac hypertrophy, PKCpiI transloca­
tion, and P-MHC expression. This is an important finding 
because transgenic mice with cardiac-specific PKCpiI 
overexpression have myocardial hypertrophy that is 
characterized by fibrosis and poor cardiac function,43 
and humans with heart failure demonstrate PKCP 
isoform activation.44
The precise mechanism or mechanisms responsible 
for the ability of Q to reduce blood pressure are unclear, 
particularly in the setting of a fixed, mechanical obstruc­
tion. One possibility is that Q preferentially dilated
resistance vessels in the upper body proximal to the 
aortic constriction. This is plausible because Q has been 
shown to evoke arterial vasodilation that is inversely 
proportional to vessel diameter.45 This is relevant 
physiologically because arterial pressure and blood flow 
are regulated to a greater degree by resistance-sized 
arteries (eg, skeletal muscle arteries) versus conductance­
sized arteries (eg, aorta).46 Although we did not find 
differences in endothelial function from arteries proximal 
to the site of aortic constriction (aorta and coronary 
arteries), this does not exclude Q-induced in vivo effects 
on the smaller peripheral arteries and arterioles in the 
skeletal muscle. A second possible explanation for our 
results concerning blood pressure involves the renal 
response to AAC. Acute AAC causes renal hypoperfusion 
that leads to increased plasma renin activity.47’4 Greater 
plasma renin activity increases circulating levels of 
angiotensin I,47 and ultimately of angiotensin II, a known 
stimulator of hypertension and cardiac hypertrophy 49 
Importantly, Q has been reported to be an inhibitor of 
angiotensin 1-converting enzyme in vitro and in vivo.50-53 
Therefore, it is possible that inhibition of angiotensin 1- 
converting enzyme by Q may have limited AAC-evoked 
hypertension.
Though our results were associated with a general 
reduction in oxidative stress (decreased levels of liver 
malondialdehyde [P = 0.05] and trend to lower protein 
carbonyls [P = 0.06] in SHAMQ and AACQ), the specific 
consequence of this reduction in oxidative stress is 
unclear. For example, previous studies have reported 
that antioxidants can reduce hypertension by improving 
vascular dilation,54-56 but lower blood pressure in our 
study was not accompanied by improved endothelial- 
dependent relaxation in the vessels we examined. 
Furthermore, inhibition of ERKI/2 and PKC in vitro 
via an antioxidant mechanism has also been reported.57 
Although we found AAC-evoked increases in PKCpiI 
translocation were prevented by Q, we did not find any 
decrease in cardiac ERKI/2 phosphorylation. Therefore,
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FIGURE 3. A, Representative 
immunoblots of PKC isoforms 
measured from LVs of rats. 
PKCa, pi, 6, and s were un­
changed among groups. B, 
PKCpiI membrane density was 
increased and translocation 
was greater in AAC versus 
SHAM. AACQ rats had similar 
PKC pil translocation compared 
to SHAMQ. *P<0.05 versus 
SHAM, AACQ, SHAMQ. C, To­
tal protein levels of PKCpiI were 
greater in AAC, but normalized 
in AACQ. *P< 0.05 versus 
SHAM, AACQ and SHAMQ. 
D, Levels of serine phosphory- 
lated PKC substrates taken from 
whole left ventricular homoge- 
nates were greater in AAC and 
AACQ versus SHAM and 
SHAMQ. However, there was 
no difference in degree of 
serine phosphorylation be­
tween AAC and AACQ controls. 
a-Tubulin was used as loading 
control and lane density of 
serine phosphorylated PKC 
substrates was normalized to 
levels of tubulin. P<0.05 versus 
SHAM, SHAMQ. c, cytosolic 
fraction; m, membrane frac­
tion; SHAM, sham operated 
and fed control chow; SHAMQ 
sham operated and fed Q-en­
riched chow; AAC, abdominal 
aortic constriction and fed con­
trol chow; AACQ, abdominal 
aortic constriction and fed Q- 
enriched chow; n = 5 for each 
group.
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our present data do not provide strong evidence for the 
reduction o f oxidative stress as a mechanism  to explain 
the effect o f Q .
A t present, the efficacy o f antioxidants such as 
vitam ins or flavonoids to lim it/prevent progression of 
card iovascu lar disease is controversia l. V itam in  C  has 
been shown to decrease vascu lar dysfunction and
hypertension in rats'^ and guinea pigs,4 whereas vitam in  
E  can decrease hypertension in humans.'"'9 However, such 
reports are tempered by a recent science advisory 
statement by the Am erican Heart Association reporting 
that more null than beneficial effects are observed in  
clin ica l trials using vitam ins C  and E .w) In  contrast, there 
are a growing number o f studies that demonstrate the
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FIGURE 4. Activation of ERK1/2 (p-ERK1/2:total ERK1/2) was 
greater in AAC and AACQ rats compared with SHAM and 
SHAMQ, however, there was no difference in ERK1/2 
activation between AAC and AACQ. *P<0.05 versus SHAM, 
SHAMQ. SHAM, sham operated and fed control chow; 
SHAMQ, sham operated and fed Q-enriched chow; AAC, 
abdominal aortic constriction and fed control chow; AACQ 
abdominal aortic constriction and fed Q-enriched chow; n = 5 
for each group.
benefits of flavonoids to prevent card iovascu lar disease. 
F o r  example, isorhapontigenin, an analog o f the flavo- 
noid resveratrol, reduces card iac hypertrophy and blood 
pressure in  pressure overloaded rats.57 Furtherm ore, Q  
attenuates blood pressure in  spontaneously hypertensive 
rats,2’61 rats with surgically induced renovascular hyper­
tension,56 rats with chronic n itric oxide synthase inh ib i­
tion ,31 deoxycorticosterone acetate-salt hypertensive 
rats,62 and rats with abdom inal aortic constriction  
(present study). Taken  together, results from the previous 
studies suggest that polyphenolic compounds such as Q  
supplemented in  the diets o f experimental an im als are 
efficacious in  reducing blood pressure. The  im plications 
of these data with regard to reduction of card iovascu lar 
disease risk in  humans with chronic consumption o f lower 
amounts o f d ietary Q  are not clear. A lthough the 
amounts o f Q  consumed by rats in  this study are 
com paratively higher than those reported in  hum ans, it 
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FIGURE 5. Animals consuming Q-supplemented diets had less 
oxidative stress as determined by liver thiobarbituric acid 
reactive substances. *P<0.05 versus SHAMQ, AACQ. SHAM, 
sham operated and fed control chow; SHAMQ sham operated 
and fed Q-enriched chow; AAC, abdominal aortic constriction 
and fed control chow; AACQ, abdominal aortic constriction 
and fed Q-enriched chow; n = 5 for each group.
been reported to be inversely associated with card iovas­
cu lar disease r isk .5’6
CONCLUSIONS
In  summ ary, our findings demonstrate that rats with 
aortic constriction fed Q-supplemented diets had attenu­
ated card iac hypertrophy, lower arteria l blood pressure, 
decreased aortic medial thickening, and normalized  
card iac P K C |3 I I  translocation. These beneficial effects 
were not accompanied by deleterious changes to cardiac 
or vascu lar function.
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